病毒载体合作与授权协议（2016-2025）

"病毒载体合作与授权协议" 全面深入分析了全球领先的生物製药公司签署的病毒载体协议，并提供前所未有的资讯取得管道。

这份经过全面修订和更新的报告详细介绍了2016年至2025年间的病毒载体协议。

本报告深入分析了企业签订病毒载体协议的原因和方式。这些协议通常包含多个组成部分，从合作研发开始，逐步推进到成果的商业化。

本报告涵盖合作、开发、研究和授权等内容。

本报告提供了自2016年以来公布的413项病毒载体交易的完整清单。报告还包括可用的财务条款以及相关方披露的实际病毒载体合作交易的线上记录连结。此外，在条件允许的情况下，记录还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件。

本报告第一章概述了病毒载体交易。

第一章概述了本报告。

第二章概述了自 2016 年以来的病毒载体交易趋势。

第三章概述了自 2016 年以来主要的病毒载体交易，并依交易总额列出。

第四章提供了病毒载体交易中最活跃的 25 家公司的完整列表，并附有简要概述，随后提供了病毒载体交易的完整列表以及公开可获取的合同文件。

第五章对自 2016 年 1 月以来已完成和已宣布的、且有公开可获取合约文件的病毒载体交易进行了全面深入的审查。

第六章对自2016年1月以来签署和公布的病毒载体合作协议进行了全面深入的回顾。本章以具体的病毒载体技术类型进行组织。

报告还包含大量表格和图表，展示了自2016年以来病毒载体交易的趋势和活动。

此外，我们还提供了一个全面的合约目录，依公司名称（A-Z）、合约类型和治疗标靶进行分类。每个合约标题都透过网路连结指向线上合约记录，并在可用的情况下指向合约文件，方便用户根据需要轻鬆存取每个合约文件。

主要优势

"病毒载体合作与授权协议" 提供读者以下主要优势：

• 了解自 2016 年以来的交易趋势
• 浏览病毒载体合作与授权协议
• 基准分析 - 确定交易市场价值
• 财务条款 - 预付款、里程碑付款、特许权使用费
• 依公司（A-Z）、协议类型和治疗领域分类的合约目录
• 以价值排名的主要交易
• 最活跃的交易撮合者
• 确定每笔交易的资产和条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款对合作伙伴公司的适用性
• 节省数百小时的研究时间

范围

• "病毒载体合作与授权协议" "病毒载体合作与授权协议" 报告旨在帮助读者深入了解全球生物製药公司之间病毒载体相关协议的趋势和结构。

"病毒载体合作与授权协议" 包含以下内容：

• 生物製药产业病毒载体交易趋势
• 製药和生物技术公司病毒载体合约记录目录
• 依价值排名的主要病毒载体合约
• 最活跃的病毒载体授权协议提供者
• "病毒载体合作与许可协议" 提供对现有合约记录的全面访问，包括合约文件（如有）。

分析合约有助于对以下内容进行尽职调查：

• 合约明确授予或选择哪些权利？
• 合约实际授予合作伙伴哪些权利？
• 授予了哪些独家权利？
• 交易的付款结构是什么？
• 销售和付款如何审计？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 智慧财产权（IPR）如何处理归属于谁？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和资讯揭露？
• 如何解决争议？
• 在什么情况下可以终止合约？
• 如果所有权发生变更会发生什么事？
• 如何约定转让许可和分包条款？
• 贵公司要求使用哪些标准条款？
• 哪些标准条款会因交易对手和交易类型而异？
• 贵公司必须在哪个司法管辖区内执行其合约？

目录

摘要整理

第一章：引言

第二章：病毒载体交易趋势

• 引言
• 历年病毒载体交易状况
• 最活跃的病毒载体交易商
• 依交易类型划分的病毒载体交易
• 依治疗领域划分的病毒载体交易
• 依行业划分的病毒载体交易
• 病毒载体交易条款
  • 病毒载体交易总额
  • 病毒载体交易预付款
  • 病毒载体交易里程碑付款
  • 病毒载体特许权使用费率

第三章 - 主要病毒载体交易

• 引言
• 以价值排名的顶级病毒载体交易

第四章 - 最活跃的病毒载体经销商

• 引言
• 最活跃的病毒载体经销商
• 最活跃的病毒载体经销商公司简介

第五章 - 病毒载体合约交易目录

• 引言
• 病毒载体合约交易目录

第六章 - 依技术类型划分的病毒载体交易

• 交易目录
• 依公司划分的病毒载体交易目录 (AZ)
• 依交易类型划分的病毒载体交易目录
• 依治疗领域划分的病毒载体交易目录
• 交易类型定义
• 关于本研究公司
• 当前合作伙伴关係
• 当前协议
• 当前合作伙伴关係近期报告标题

Viral Vector Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the viral vector deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of viral vector deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter viral vector deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 413 viral vector deals announced since 2016 including financial terms where available including links to online deal records of actual viral vector partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of viral vector dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in viral vector dealmaking since 2016.

Chapter 3 provides an overview of the leading viral vector deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in viral vector dealmaking with a brief summary followed by a comprehensive listing of viral vector deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of viral vector deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of viral vector partnering deals signed and announced since Jan 2016. The chapter is organized by specific viral vector technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in viral vector deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Viral Vector Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse viral vector collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Viral Vector Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of viral vector trends and structure of deals entered into by leading biopharma companies worldwide.

Viral Vector Collaboration and Licensing Deals includes:

• Trends in viral vector dealmaking in the biopharma industry
• Directory of viral vector deal records covering pharmaceutical and biotechnology
• The leading viral vector deals by value
• Most active viral vector licensing dealmakers
• Viral Vector Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in viral vector dealmaking

• 2.1. Introduction
• 2.2. Viral vector deals over the years
• 2.3. Most active viral vector dealmakers
• 2.4. Viral vector deals by deal type
• 2.5. Viral vector deals by therapy area
• 2.6. Viral vector deals by industry sector
• 2.7. Deal terms for viral vector deals
  • 2.7.1 Viral vector deals headline values
  • 2.7.2 Viral vector deal upfront payments
  • 2.7.3 Viral vector deal milestone payments
  • 2.7.4 Viral vector royalty rates

Chapter 3 - Leading viral vector deals

• 3.1. Introduction
• 3.2. Top viral vector deals by value

Chapter 4 - Most active viral vector dealmakers

• 4.1. Introduction
• 4.2. Most active viral vector dealmakers
• 4.3. Most active viral vector deals company profiles

Chapter 5 - Viral vector contracts dealmaking directory

• 5.1. Introduction
• 5.2. Viral vector contracts dealmaking directory

Chapter 6 - Viral vector dealmaking by technology type

• Deal directory
• Deal directory - Viral vector deals by company A-Z
• Deal directory - Viral vector deals by deal type
• Deal directory - Viral vector deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Viral vector deals since 2016
• Figure 2: Active viral vector dealmaking activity - 2016 - 2025
• Figure 3: Viral vector deals by deal type since 2016
• Figure 4: Viral vector deals by therapy area since 2016
• Figure 5: Viral vector deals by industry sector since 2016
• Figure 6: Viral vector deals with a headline value
• Figure 7: Viral vector deals with an upfront value
• Figure 8: Viral vector deals with a milestone value
• Figure 9: Viral vector deals with a royalty rate value
• Figure 10: Top viral vector deals by value since 2016
• Figure 11: Most active viral vector dealmakers 2016 - 2025
• Figure 12: Viral vector deals by technology type since 2016